Crossmark

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

Crossref DOI link: https://doi.org/10.1136/annrheumdis-2014-205847

Published Print: 2016-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Curtis, Jeffrey R

Lee, Eun Bong

Kaplan, Irina V

Kwok, Kenneth

Geier, Jamie

Benda, Birgitta

Soma, Koshika

Wang, Lisy

Riese, Richard
License Information

Text and Data Mining valid from 2016-05-01

Text and Data Mining valid from 2016-05-01

Version of Record valid from 2015-04-22
More Information

This article is maintained by: Elsevier

Article Title: Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

Journal Title: Annals of the Rheumatic Diseases

CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/annrheumdis-2014-205847

Content Type: article

Copyright: Copyright © 2016 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.